RLMD— RELMADA THERAPEUTICS, INC.

MaterialsPharmaceuticals$518M mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Research and development	$26.9M-41.8%	$46.2M-15.7%	$54.8M-51.6%	$113.3M
General and administrative	$32.2M-14.6%	$37.7M-22.9%	$48.9M+2.0%	$47.9M
Total operating expenses	$59.1M-29.6%	$83.9M-19.1%	$103.7M-35.7%	$161.2M
Loss from operations	-$59.1M+29.6%	-$83.9M+19.1%	-$103.7M+35.7%	-$161.2M
Interest/investment income, net	$1.4M-60.5%	$3.5M-31.5%	$5.2M+93.7%	$2.7M
Realized (loss) gain on short-term investments	-$79K-121.1%	$375K+109.2%	-$4.1M-594.1%	-$586K
Unrealized gain on short-term investments	$398K+5813.2%	$7K-99.8%	$3.8M+190.6%	-$4.2M
Total other income (expenses), net	$1.7M-56.2%	$3.9M-20.3%	$4.9M+16.8%	$4.2M
Net loss	-$57.4M+28.3%	-$80.0M+19.0%	-$98.8M+37.1%	-$157.0M
Loss per common share – basic (in Dollars per share)	-$1.45+45.3%	-$2.65+19.2%	-$3.28+38.1%	-$5.30
Loss per common share – diluted (in Dollars per share)	-$1.45+45.3%	-$2.65+19.2%	-$3.28	—
Weighted average number of common shares outstanding – basic (in Shares)	39.5M+30.9%	30.2M+0.2%	30.1M+1.6%	29.6M
Weighted average number of common shares outstanding – diluted (in Shares)	39.5M+30.9%	30.2M+0.2%	30.1M	—

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 12 more years of annual history and full quarterly detail on Pro.

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.